In Ohio, the Cleveland Clinic joined the Circulating Cell-free Genome Atlas, a national clinical trial that is looking for 7,000 cancer patients and 3,000 healthy patients in the U.S. Their goal is to analyze DNA and RNA in the blood and build a database that will help with detecting cancer early on when it is easier to cure. Researchers believe that using genome sequencing from blood samples could possibly replace x-rays for early cancer detection. Funded by a company in California, GRAIL, Inc., the project will be looking for molecule patterns in the blood for specific types of cancers.
Latest article
Dutch Queen promotes biobased building materials
In the Netherlands, Dutch Queen consort Máxima visited two Uden worksites promoting biobased building materials made from Netherlands fiber crops.
The March 26 visit...
ReefCircular launches crowdfunding campaign for shell bioconcrete
In Denmark, ReefCircular, a company developing a shell-based bioconcrete to help restore marine habitats, has launched a crowdfunding campaign on Kickstarter.
The company’s bioconcrete...
Aleph Farms raises $29 million for lab-grown steak
In Israel, cultivated meat producer Aleph Farms has raised $29 million to expand production at its Rehovot pilot plant and expand production into Europe...